Page 372 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

328 MEDICAMENTINDUISANT OUSTABILISANTDES COUPURES DE L'ADN

MINISCI F. et PORTA O., Advances in Heterocyclic Chem., 1974, 16, 1713-1718.
WANI M. et al., Synthesis and biological activity of camptothecin analogues, J. Med.
Chem., 1980, 23, 554-560.
WANI M. et al., Isolation of 11-hydroxycamptothecin from Camptotheca acuminata, total
synthesis and biological activity, J. Med. Chem., 1986, 29, 1553-1555.
KINGSBURY W., Synthesis of water-soluble (aminoalkyl)camptothecin analogues,J. Med.
Chem., 1991, 34, 98-107.
SAWADA S. et al., Synthesis and antitumor activity of 20(S)-camptothecin derivatives,
Chem. Pharm. Bull., 1991, 39, 1446-1454.
SAWADA S. et al., Synthesis and antitumor activity of 7-C-substituted camptothecins,
Chem. Pharm. Bull., 1991, 39, 2574-2580.

IRINOTÉCAN
YAKULT HONSHA Co, brevets Jap. 85 19.790 (1985) et US 4.604.463.
KAWATO Y. et al., Intracellular roles of SN-38, a metabolite of the camptothecin derivate
CPT-11, CancerRes., 1991, 51, 4187-4191.
KAWATO Y. et al., Antitumor activity of CPT-11, against human tumor xenografts in nude
mice, Cancer Chemother. Pharmacol., 1991, 28, 192-198.
SAWADA S. et al., A-ring modified and 7,10-disubstituted camptothecins, Chem. Pharm.
Bull., 1991, 39, 3183-3188.
RIVORY L et ROBERT J., Molecular, cellular and clinical aspects of the pharmacology
of camptothecin and its derivatives, Pharmacol. Ther., 1995, 68, 269-296 ; Pharma-
cologie de la camptothécine et de ses dérivés, Bull. Cancer, 1995, 82, 265-285 ; Iden-
tification and kinetics of a glucuronide metabolite of SN-38 in human plasma after
administration of the camptothecin derivate irinotecan, Cancer Chemother. Pharma-
col., 1995, 36, 176-179.
SAWADA S. et al., Synthesis of CPT-11, Ann. N.Y. Acad. Sci., 1996, 803, 13-28.
Society of Japanese Pharmacopoiea/Japanese Ministry of Health and Welfare, Summary
Basis of approval for lrinotecan hydrochloride, YAKUJI NIPPO Ltd, Tokyo, 1996.
BEDESCHI A. et al., Water-soluble camptothecin derivatives, Drugs Future, 1997, 22,
1259-1266.
TOPOTÉCAN
SMITHKLINE Co, brevet européen 321.122 (1989).
CABRI W. et al., New high yield semisynthetic approach to 9-aminocamptothecin, Tetra-
hedron Lett., 1995, 36, 9197-9200.
CREEMERS G. et al., Topotecan, an active drug in the second-line treatment of epithelial
ovarian cancer, J. Clin. Oncol., 1996, 14, 3056-3061.
HERBEN V. et al., Clinlcal pharmacokinetlcs of topotecan, Clin. Pharmacokinetic., 1996,
31, 85-102.
European Agency for the Evaluation of Medicinal Products, rapports EPAR-CPMP
709/96 et 642/96, Londres, 1996.
KUDELKA A. et al., Phase Il study of lntravenous topotecan, J. Clln. Oncol., 1996, 14,
1552-1557.